QUOTE AND NEWS
Benzinga  Nov 21  Comment 
In a report published Friday, Bank of America analyst Ying Huang reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN), and raised the price target from $418.00 to $462.00. In the report, Bank of America noted, “We are raising...
Benzinga  Nov 20  Comment 
In a report published Thursday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN), and raised the price target from $390.00 to $450.00. In the report, Brean Capital noted, “At the AHA...
newratings.com  Nov 20  Comment 
PARIS (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNYNF, SNY) Thursday said the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy designation to its investigational dupilumab, which is indicated for the...
Jutia Group  Nov 19  Comment 
[PR Newswire] - PARIS AND TARRYTOWN, N.Y., Nov. 19, 2014 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed ... Read more on this. ...
TheStreet.com  Nov 18  Comment 
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener. NEW YORK (TheStreet) -- Here are some of the hot stocks Jim Cramer talked about on Monday's Mad Money on CNBC: REGN data by YCharts...
Market Intelligence Center  Nov 14  Comment 
For a hedged play on Regeneron Pharmaceuticals Inc (REGN) MarketIntelligenceCenter.com’s patented trade-picking algorithms selected a Jan. '15 $400.00 covered call for a net debit in the $381.63 area. That is also the break-even stock price for...
StreetInsider.com  Nov 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Regeneron+%28REGN%29%2C+Sanofi+%28SNY%29+Report+Dupilumab+Met+Primary+Endpoint+in+Phase+2b/9998050.html for the full story.
Motley Fool  Nov 5  Comment 
Regeneron Pharmaceuticals guides for 2014 U.S. Eylea sales toward the low end of previous guidance, causing shares to slip.
TheStreet.com  Nov 4  Comment 
NEW YORK (TheStreet) -- Regeneron Pharmaceuticals Inc.  shares are falling, down 5.2% to $374.53 in market trading on Tuesday, after the biopharmaceutical company lowered the top line of the full year forecast for its breakthrough macular...




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki